COMPANY

Precision BioSciences

HQ: Durham, NC source · precisionbiosciences.com ↗ · Southeast

Keywords: hepatitis B Duchenne muscular dystrophy HEPATITIS B CHRONIC Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD Chronic HBV Infection CD19 Expressing Malignancies Hematologic Malignancy Relapsed/Refractory Multiple Myeloma Relapsed Non-Hodgkin's Lymphoma Chronic Lymphoid Leukemia in Relapse Non-Hodgkin's Lymphoma Refractory Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Leukemia, Lymphocytic, Chronic B-cell Chronic Lymphocytic Leukemia B-cell Non Hodgkin Lymphoma Small Lymphocytic Lymphoma PBGENE-HBV PBCAR19B PBCAR269A PBCAR20A

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

$75.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Apr 24, 2026 Trial start 1: PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) source ↗
Dec 25, 2025 Trial start —: A Long-term Observational Study in Participants Who Have Received PBGENE-HBV source ↗
Nov 10, 2025 Raise Follow-on offering: $75M (total, as published), announced Nov 10, 2025. Source: SEC filing. source ↗
Nov 14, 2024 Trial start 1: Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B source ↗
Jun 16, 2021 Trial start Phase 1: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies source ↗
Apr 30, 2020 Trial start Phase 1: A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma source ↗
Mar 24, 2020 Trial start Phase 1/Phase 2: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL source ↗

Upcoming milestones

2026-12 (ESTIMATED) · 1 · Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B · NCT06680232
2029-11 (ESTIMATED) · 1 · PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) · NCT07429240
2040-01 (ESTIMATED) · · A Long-term Observational Study in Participants Who Have Received PBGENE-HBV · NCT07254208

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $75.0M. Last 2 years.

Nov 10, 2025 Follow-on offering: $75M (total, as published), announced Nov 10, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06680232	Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B	1	Recruiting	Nov 14, 2024	2026-12 (estimated)
NCT07429240	PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)	1	Recruiting	Apr 24, 2026	2029-11 (estimated)
NCT07254208	A Long-term Observational Study in Participants Who Have Received PBGENE-HBV	Not listed	Enrolling by invitation	Dec 25, 2025	2040-01 (estimated)
NCT04649112	Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies	Phase 1	Completed	Jun 16, 2021	Dec 22, 2022 (actual)
NCT04171843	A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma	Phase 1	Terminated	Apr 30, 2020	Oct 19, 2022 (actual)
NCT04030195	Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL	Phase 1/Phase 2	Completed	Mar 24, 2020	Jun 24, 2021 (actual)